DK1501856T3 - Anti-HER2 antistofvarianter - Google Patents

Anti-HER2 antistofvarianter

Info

Publication number
DK1501856T3
DK1501856T3 DK03721610.8T DK03721610T DK1501856T3 DK 1501856 T3 DK1501856 T3 DK 1501856T3 DK 03721610 T DK03721610 T DK 03721610T DK 1501856 T3 DK1501856 T3 DK 1501856T3
Authority
DK
Denmark
Prior art keywords
her2 antibody
antibody variants
variants
her2
antibody
Prior art date
Application number
DK03721610.8T
Other languages
English (en)
Inventor
Henry B Lowman
Resi B Gerstner
Paul J Carter
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1501856T3 publication Critical patent/DK1501856T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/18—Arrangements for indicating condition of container contents, e.g. sterile condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/30—Printed labels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03721610.8T 2002-04-10 2003-04-09 Anti-HER2 antistofvarianter DK1501856T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37160902P 2002-04-10 2002-04-10
PCT/US2003/011031 WO2003087131A2 (en) 2002-04-10 2003-04-09 Anti-her2 antibody variants

Publications (1)

Publication Number Publication Date
DK1501856T3 true DK1501856T3 (da) 2013-03-25

Family

ID=29250707

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03721610.8T DK1501856T3 (da) 2002-04-10 2003-04-09 Anti-HER2 antistofvarianter

Country Status (10)

Country Link
US (6) US7435797B2 (da)
EP (2) EP1501856B1 (da)
JP (4) JP2005522514A (da)
AU (2) AU2003224916B2 (da)
CA (1) CA2481515C (da)
DK (1) DK1501856T3 (da)
ES (2) ES2429112T3 (da)
IL (2) IL164417A (da)
SI (2) SI2289942T1 (da)
WO (1) WO2003087131A2 (da)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7608681B2 (en) * 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
CN1447696A (zh) * 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
WO2003014960A2 (en) * 2001-08-03 2003-02-20 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
JP2005522514A (ja) * 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
CA2555820C (en) * 2004-02-19 2016-01-19 Genentech, Inc. Cdr-repaired antibodies
HRP20141111T1 (hr) 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
JP2008515889A (ja) * 2004-10-05 2008-05-15 ジェネンテック・インコーポレーテッド 毒性の低下した治療剤
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2710439T3 (es) 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
KR101434682B1 (ko) * 2005-12-02 2014-08-27 제넨테크, 인크. 결합 폴리펩티드 및 이들의 용도
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
ES2392630T3 (es) 2006-08-21 2012-12-12 F. Hoffmann-La Roche Ag Terapia antitumoral con anticuerpos anti-VEGF
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
SG10201808730VA (en) † 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
US20100183615A1 (en) * 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
WO2008150485A2 (en) * 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
WO2011084496A1 (en) * 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
CN102167742B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012075581A1 (en) 2010-12-06 2012-06-14 Ym Biosciences Inc. Antibodies selective for cells presenting erbb2 at high density
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
PT4241849T (pt) 2011-10-14 2024-10-30 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
CN108034006A (zh) * 2012-01-13 2018-05-15 乌利班-马克西姆利安大学 双抗原诱导的双功能互补作用
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
KR101505157B1 (ko) 2012-05-08 2015-03-24 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
ES2738310T3 (es) 2012-10-12 2020-01-21 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
WO2014070957A1 (en) 2012-10-30 2014-05-08 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
AU2014262566A1 (en) * 2013-05-08 2015-11-12 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
MX379030B (es) 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
CA2925677A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Bispecific her2 antibodies and methods of use
SI3604333T1 (sl) 2014-03-11 2021-08-31 Molecular Templates, Inc. Proteini, ki obsegajo aminoterminalne proksimalne Shiga toksin podenota A efektorske regije in celico-ciljajoče vezavne regije imunogobulinskega tipa, ki so sposobne specifične vezave CD38
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
SG11201608192SA (en) * 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
CN106163558A (zh) 2014-04-25 2016-11-23 豪夫迈·罗氏有限公司 用曲妥珠单抗‑mcc‑dm1和帕妥珠单抗治疗早期乳腺癌的方法
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR101515535B1 (ko) 2015-01-28 2015-05-06 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
CN105985435B (zh) 2015-01-30 2019-10-15 嘉和生物药业有限公司 全人源her2抗体的突变抗体及其编码基因和应用
SI3302551T1 (sl) 2015-05-30 2024-10-30 F. Hoffmann-La Roche Ag Metode zdravljenja predhodno nezdravljenega her2-pozitivnega metastatskega raka dojk
HUE051246T2 (hu) 2015-05-30 2021-03-01 Molecular Templates Inc Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
HUE073235T2 (hu) * 2015-06-17 2026-01-28 Hoffmann La Roche Anti-HER2 antitestek és alkalmazási eljárások
MX2018001208A (es) 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
SG11201802769RA (en) 2015-10-29 2018-05-30 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CN110505880A (zh) 2016-11-04 2019-11-26 基因泰克公司 Her2阳性乳腺癌的治疗
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
EP3562844A1 (en) 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
MY189536A (en) 2017-01-17 2022-02-16 Hoffmann La Roche Subcutaneous her2 antibody formulations
JP7082424B2 (ja) 2017-01-25 2022-06-08 モレキュラー テンプレーツ，インク． 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
CN110382696B (zh) * 2017-03-07 2024-04-19 豪夫迈·罗氏有限公司 发现替代性抗原特异性抗体变体的方法
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CA3177215A1 (en) 2017-09-19 2019-03-28 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
KR102871791B1 (ko) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
EP3988574A4 (en) * 2019-02-03 2022-10-12 Shanghai Bao Pharmaceuticals Co., Ltd. AGAINST HER2 BI-SPECIFIC ANTIBODIES AND THEIR USE
BR112022011357A2 (pt) 2019-12-13 2022-08-23 Genentech Inc Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
JP7856312B2 (ja) * 2020-01-23 2026-05-11 バイオアトラ インコーポレイテッド 条件的に活性な抗ｈｅｒ２抗体、抗体断片、それらの免疫コンジュゲート、およびそれらの使用
JP7737996B2 (ja) * 2020-01-23 2025-09-11 エクスマ バイオテック コーポレイション Ｈｅｒ２に対するキメラ抗原受容体およびその使用方法
WO2021219046A1 (zh) * 2020-04-30 2021-11-04 正大天晴药业集团股份有限公司 靶向her2的抗原结合构建体及用途
EP4171748A1 (en) 2020-06-29 2023-05-03 Genentech, Inc. Pertuzumab plus trastuzumab fixed dose combination
CN119792564A (zh) 2020-08-13 2025-04-11 正大天晴药业集团股份有限公司 抗体药物偶联物
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
WO2022084560A1 (en) 2020-10-25 2022-04-28 Araris Biotech Ag Means and methods for producing antibody-linker conjugates
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
KR20230147092A (ko) * 2021-01-22 2023-10-20 바이원큐어 테라퓨틱스, 인크. 항-her-2/trop-2 작제물 및 이의 용도
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
JP2025523630A (ja) 2022-07-04 2025-07-23 ブイアイビー ブイゼットダブリュ 血液－脳脊髄液関門通過抗体
CA3263050A1 (en) 2022-07-30 2024-02-08 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradation and their methods of use
JP2025531924A (ja) * 2022-09-20 2025-09-25 普米斯生物技術（珠海）有限公司 抗ｈｅｒ２抗体およびこの使用
EP4653017A1 (en) 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
WO2026032417A1 (zh) * 2024-08-08 2026-02-12 石药集团巨石生物制药有限公司 Gspt1降解剂和含有gspt1降解剂的抗体偶联物及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0171407B1 (en) 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Improvements relating to growth factors
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0494135B1 (en) 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
CA2120745A1 (en) 1992-06-30 1994-01-06 Philip G. Kasprzyk A combination of anti-erbb-2 monoclonal antibodies and method of using
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
ATE186219T1 (de) 1993-03-24 1999-11-15 Berlex Biosciences Kombination von antihormonale und bindende moleküle zur krebsbehandlung
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
CA2207869A1 (en) 1994-12-02 1996-06-06 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5837234A (en) * 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
WO2003068801A2 (en) 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates
JP2005522514A (ja) * 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体

Also Published As

Publication number Publication date
ES2429112T3 (es) 2013-11-13
HK1069586A1 (en) 2005-05-27
JP2013006871A (ja) 2013-01-10
HK1153763A1 (en) 2012-04-05
EP1501856A2 (en) 2005-02-02
JP5782419B2 (ja) 2015-09-24
AU2009201370B2 (en) 2012-05-17
EP2289942A3 (en) 2011-06-08
IL164417A0 (en) 2005-12-18
IL202348A (en) 2015-05-31
JP2014218505A (ja) 2014-11-20
SI1501856T1 (sl) 2013-04-30
US7435797B2 (en) 2008-10-14
US20090187007A1 (en) 2009-07-23
AU2009201370A1 (en) 2009-04-30
SI2289942T1 (sl) 2013-11-29
CA2481515A1 (en) 2003-10-23
CA2481515C (en) 2013-10-01
WO2003087131A3 (en) 2004-12-09
US7850966B2 (en) 2010-12-14
EP1501856B1 (en) 2012-12-19
EP1501856A4 (en) 2007-06-06
US8840896B2 (en) 2014-09-23
AU2003224916A1 (en) 2003-10-27
IL202348A0 (en) 2011-08-01
WO2003087131A2 (en) 2003-10-23
US20180201692A1 (en) 2018-07-19
US20030228663A1 (en) 2003-12-11
US20110159014A1 (en) 2011-06-30
ES2401428T3 (es) 2013-04-19
EP2289942A2 (en) 2011-03-02
US20160060353A1 (en) 2016-03-03
US20170166656A1 (en) 2017-06-15
JP2005522514A (ja) 2005-07-28
JP2009149661A (ja) 2009-07-09
EP2289942B1 (en) 2013-07-31
AU2003224916B2 (en) 2009-01-08
IL164417A (en) 2010-05-31

Similar Documents

Publication Publication Date Title
NO20044347L (no) Anti-alfavbeta6-antistoff
IL202348A0 (en) Anti-her2 antibody variants
DK1599504T3 (da) Modificeret antistof
NO2016001I1 (no) Trastuzumab emtansin
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
IS6982A (is) Mótefni gegn VLA-1
EE200300179A (et) Humaniseeritud LT-ß-R-i vastased antikehad
DE602004022855D1 (de) Interleukin-10-antikörper
EP1616881A4 (en) ANTI-MPL ANTIBODY
EP1499352A4 (en) ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
IS8342A (is) Mótefni gegn M-CSF
AU2003217912A8 (en) Antibody optimization
IS2940B (is) Mótefni gegn CD40
CY2012019I2 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
DE50305301D1 (de) Einspritzventil
EE200300569A (et) CD44v6-spetsiifilised antikehad
DE60236403D1 (de) Tourbillonmechanismus
NO20044145L (no) Assay for anti-INGAP antistoffer
GB0306618D0 (en) Antibody
DE502004000456D1 (de) Ventilsteuerung
FI20020807A0 (fi) Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
LU90915B1 (de) Sektionaltor
FR2844817B1 (fr) Element de coffrage